Ask AI
EGFRm NSCLC Progression on Osimertinib

CE / CME

Management of a Patient With EGFR-Mutated NSCLC and Progression on First-line Osimertinib

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Released: April 17, 2026

Expiration: October 16, 2026

Activity

Progress
1 2
Course Completed

  1. Passaro A, Leighl N, Blackhall F, et al. ESMO expert consensus statements on the management of EGFR mutant non‑small‑cell lung cancer. Ann Oncol. 2022;33:466‑487.
  2. Koyama K, Miura S, Watanabe S, et al. Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC. Sci Rep. 2022;12:6367.
  3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 5.2026. nccn.org. Accessed April 8, 2026.
  4. Hernández de Córdoba I, Mielgo-Rubio X, Cejas P, et al. Transformation to neuroendocrine phenotype in non-small-cell lung carcinoma: a literature review. Int J Mol Sci. 2025;26:5096.
  5. Peled N, Tufman A, Sequist LV, et al. COMPEL: osimertinib plus platinum‑based chemotherapy in patients with EGFR‑mutated advanced NSCLC and progression on first‑line osimertinib. ESMO Open. 2025;10:105807.
  6. US Food and Drug Administration. FDA grants accelerated approval to datopotamab deruxtecan-dlnk for lung cancer. fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-datopotamab-deruxtecan-dlnk-egfr-mutated-non-small-cell-lung-cancer. Accessed April 7, 2026.
  7. Datopotamab deruxtecan [prescribing information]. Basking Ridge, NJ: Daiichi Sankyo, Inc; 2025.
  8. Ahn M‑J, Lisberg A, Goto Y, et al. A pooled analysis of datopotamab deruxtecan in patients with EGFR‑mutated NSCLC. J Thorac Oncol. 2025;20:1669‑1682.